| Literature DB >> 26887245 |
Bruno Rocha Pribul1, Marcia Lima Festivo2, Miliane Moreira Soares de Souza3, Dalia dos Prazeres Rodrigues2.
Abstract
Non-typhoidal salmonellosis is an important zoonotic disease caused by Salmonella enterica. The aim of this study was to investigate the prevalence of plasmid-mediated quinolone resistance in Salmonella spp. and its association with fluoroquinolone susceptibility in Brazil. A total of 129 NTS isolates (samples from human origin, food from animal origin, environmental, and animal) grouped as from animal (n=62) and human (n=67) food were evaluated between 2009 and 2013. These isolates were investigated through serotyping, antimicrobial susceptibility testing, and the presence of plasmid-mediated quinolone resistance (PMQR) genes (qnr, aac(6')-Ib) and associated integron genes (integrase, and conserved integron region). Resistance to quinolones and/or fluoroquinolones, from first to third generations, was observed. Fifteen isolates were positive for the presence of qnr genes (8 qnrS, 6 qnrB, and 1 qnrD) and twenty three of aac(6')-Ib. The conserved integron region was detected in 67 isolates as variable regions, from ±600 to >1000pb. The spread of NTS involving PMQR carriers is of serious concern and should be carefully monitored.Entities:
Keywords: Foodborne diseases; Quinolone resistance; Salmonella spp.
Mesh:
Substances:
Year: 2016 PMID: 26887245 PMCID: PMC4822777 DOI: 10.1016/j.bjm.2015.04.001
Source DB: PubMed Journal: Braz J Microbiol ISSN: 1517-8382 Impact factor: 2.476
Sequence of oligonucleotide primers used in this study.
| Primers | Primer sequences (5′-3′) | Target gene | Amplicon size (bp) | Reference |
|---|---|---|---|---|
| QnrA-F | ATTTCTCACGCCAGGATTTG | 516 | Jacoby et al. | |
| QnrA-R | GATCGGCAAAGGTTAGGTCA | |||
| QnrB-F | GATCGTGAAAGCCAGAAAGG | 469 | Jacoby et al. | |
| QnrB-R | ACGATGCCTGGTAGTTGTCC | |||
| QnrC-F | GGGTTGTACATTTATTGAATCG | 307 | Kim et al. | |
| QnrC-R | CACCTACCCATTTATTTTCA | |||
| QnrD-F | CGAGATCAATTTACGGGGAATA | 582 | Cavaco et al. | |
| QnrD-R | AACAAGCTGAAGCGCCTG | |||
| QnrS-F | ACGACATTCGTCAACTGCAA | 417 | Jacoby et al. | |
| QnrS-R | TAAATTGGCACCCTGTAGGC | |||
| AAC(6′)-Ib-F | TATGAGTGGCTAAATCGAT | 482 | Park et al. | |
| AAC(6′)-Ib-R | CCCGCTTTCTCGTAGCA | |||
| Integrase-F | CCTCCCGCACGATGATC | 250 | Peirano et al. | |
| Integrase-R | TCCACGCATCGTCAGGC | |||
| Integron-3 | AAGCAGACTTGACCTGA | Variable | Peirano et al. | |
| Integron-5 | GGCATCCAAGCAGCAAG |
Distribution of quinolone-resistant Salmonella spp. serovars isolated from food chain diseases.
| Year | Number of NTS | |||||
|---|---|---|---|---|---|---|
| Human | Food | Environment | Animal | |||
| 2013 | 2 | – | – | – | 2 | |
| 2012 | 24 | 14 | 1 | 1 | 40 | |
| 2011 | 7 | 2 | 2 | – | 11 | |
| 2010 | – | 4 | – | 1 | 5 | |
| 2009 | 2 | 2 | 1 | 1 | 6 | |
| 2013 | 3 | – | – | – | 3 | |
| 2012 | 20 | 1 | – | – | 21 | |
| 2009 | 1 | – | – | – | 1 | |
| 2012 | 2 | 1 | – | – | 3 | |
| 2011 | – | 1 | – | – | 1 | |
| 2012 | 1 | – | – | 2 | 3 | |
| 2012 | 1 | – | 1 | – | 2 | |
| 2010 | – | 1 | – | – | 1 | |
| 2012 | – | 2 | – | – | 2 | |
| 2011 | – | – | – | 1 | 1 | |
| Others | 2013 | 1 | – | – | – | 1 |
| 2012 | 3 | 8 | 6 | – | 17 | |
| 2011 | – | 1 | 1 | 1 | 3 | |
| 2010 | – | 1 | 1 | 2 | 4 | |
| 2009 | – | 1 | – | 2 | 3 | |
| 67 | 39 | 14 | 32 | 152 | ||
Non-typhoid Salmonella.
Quinolone susceptibility of qnr-positive isolates.
| Isolate | Source | PMQR | Integron | MIC (μg/mL) | ||||
|---|---|---|---|---|---|---|---|---|
| Cip | Nal | Eno | Lvx | Ofl | ||||
| H | ≥2 | ≥128 | ≥4 | ≥2 | ≥4 | |||
| H | ±900 bp | ≥2 | ≥128 | ≥4 | ≤0.06 | ≤0.25 | ||
| H | ≥2 | ≥128 | ≥4 | ≥2 | ≥4 | |||
| H | >1000 bp | ≤0.5 | ≥128 | ≤1 | ≤0.06 | ≤0.06 | ||
| F | ≤0.5 | ≤64 | ≤2 | ≤0.06 | ≤0.06 | |||
| F | ≤0.03 | ≤32 | ≤0.06 | ≤0.06 | ≤0.06 | |||
| A | ±900 bp | ≤0.5 | ≥128 | ≤0.5 | ≤0.06 | ≤0.06 | ||
| H | ≤0.5 | ≥128 | ≥4 | ≤0.06 | ≤0.12 | |||
| H | ≤0.5 | ≤32 | ≤2 | ≤0.06 | ≤0.06 | |||
| F | ≤0.5 | ≥128 | ≥4 | ≤0.06 | ≤0.06 | |||
| E | ≤0.5 | ≥128 | ≤2 | ≤0.06 | ≤0.06 | |||
| H | ≤1 | ≤64 | ≤2 | ≤0.06 | ≤0.06 | |||
| H | ±800 bp | ≤0.25 | ≥128 | ≤1 | ≤0.06 | ≤0.06 | ||
| H | >1000 bp | ≤1 | ≥128 | ≤2 | ≤0.06 | ≤0.25 | ||
| H | ≥2 | ≥128 | ≥4 | ≤2 | ≤2 | |||
| F | ≥2 | ≥128 | ≥4 | ≤2 | ≤2 | |||
| E | ±900 bp | ≥2 | ≥128 | ≥4 | ≤2 | ≤2 | ||
| A | ±900 bp | ≥2 | ≥128 | ≥4 | ≤2 | ≤2 | ||
| H | ±900 bp | ≥2 | ≥128 | ≥4 | ≥4 | ≥4 | ||
| F | ≥2 | ≥128 | ≥4 | ≥4 | ≥4 | |||
| F | ±900 bp | ≥2 | ≥128 | ≥4 | ≤1 | ≤1 | ||
| H | ±800 bp | ≤1 | ≥128 | ≥4 | ≥4 | ≤2 | ||
| H | >1000 bp | ≤0.25 | ≥128 | ≤0.25 | ≤0.12 | ≤0.12 | ||
| H | ≤0.5 | ≥128 | ≤2 | ≤0.12 | ≤0.12 | |||
| H | ±800 bp | ≥2 | ≥128 | ≥4 | ≤1 | ≤1 | ||
| H | ≥2 | ≤64 | ≥4 | ≤1 | ≤2 | |||
| F | ≤0.5 | ≥128 | ≤2 | ≤0.06 | ≤0.06 | |||
| E | ≤0.25 | ≤8 | ≤0.06 | ≤0.06 | ≤0.06 | |||
| F | ±600 bp | ≤0.5 | ≤32 | ≤2 | ≤0.06 | ≤0.06 | ||
| E | ≤0.5 | ≤32 | ≤1 | ≤0.06 | ≤0.06 | |||
| A | ±800 bp | ≤0.5 | ≥128 | ≤1 | ≤0.06 | ≤0.06 | ||
H, human; F, food; E, environment; A, animal; CIP, ciprofloxacin; NAL, nalidixic acid; ENO, enrofloxacin; LVX, levofloxacin; OFL, ofloxacin; MIC, minimal inhibitory concentration; DD, diffusion disc.
Variable region.
Isolate quantity.